Atea Pharmaceuticals (AVIR) Competitors $2.91 +0.01 (+0.34%) Closing price 04:00 PM EasternExtended Trading$2.85 -0.06 (-2.06%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. RLAY, TSHA, CRMD, URGN, RZLT, ABUS, PHAT, KOD, VALN, and XNCRShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Relay Therapeutics (RLAY), Taysha Gene Therapies (TSHA), CorMedix (CRMD), Urogen Pharma (URGN), Rezolute (RZLT), Arbutus Biopharma (ABUS), Phathom Pharmaceuticals (PHAT), Kodiak Sciences (KOD), Valneva (VALN), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Relay Therapeutics Taysha Gene Therapies CorMedix Urogen Pharma Rezolute Arbutus Biopharma Phathom Pharmaceuticals Kodiak Sciences Valneva Xencor Atea Pharmaceuticals (NASDAQ:AVIR) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Is AVIR or RLAY more profitable? Atea Pharmaceuticals' return on equity of -32.55% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -32.55% -30.47% Relay Therapeutics N/A -41.49%-37.43% Does the media prefer AVIR or RLAY? In the previous week, Relay Therapeutics had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 1 mentions for Relay Therapeutics and 0 mentions for Atea Pharmaceuticals. Relay Therapeutics' average media sentiment score of 1.67 beat Atea Pharmaceuticals' score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Atea Pharmaceuticals Neutral Relay Therapeutics Very Positive Which has stronger earnings & valuation, AVIR or RLAY? Atea Pharmaceuticals has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.81Relay Therapeutics$10.01M96.28-$337.71M-$1.95-2.87 Which has more volatility & risk, AVIR or RLAY? Atea Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Do institutionals & insiders hold more shares of AVIR or RLAY? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate AVIR or RLAY? Atea Pharmaceuticals presently has a consensus target price of $6.00, indicating a potential upside of 106.19%. Relay Therapeutics has a consensus target price of $16.50, indicating a potential upside of 195.17%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Relay Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 SummaryRelay Therapeutics beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.14M$3.36B$6.16B$10.57BDividend YieldN/A2.28%5.50%4.66%P/E Ratio-1.8122.0285.5827.12Price / SalesN/A464.24612.74135.85Price / CashN/A46.3226.3031.10Price / Book0.569.9612.876.67Net Income-$168.38M-$52.42M$3.30B$276.23M7 Day Performance-0.34%5.95%4.80%3.31%1 Month Performance-13.65%11.59%8.11%10.76%1 Year Performance-15.90%25.01%75.85%33.58% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals1.8634 of 5 stars$2.91+0.3%$6.00+106.2%-16.2%$230.14MN/A-1.8170Positive NewsRLAYRelay Therapeutics2.8477 of 5 stars$5.19+0.4%$16.50+217.9%-16.1%$891.37M$10.01M-2.66330TSHATaysha Gene Therapies2.5362 of 5 stars$3.16-2.8%$8.29+162.2%+136.8%$886.58M$8.33M-9.29180News CoverageGap UpCRMDCorMedix3.1078 of 5 stars$11.85+4.9%$18.00+51.9%+27.4%$882.07M$121.48M15.8030Analyst DowngradeURGNUrogen Pharma3.9461 of 5 stars$19.14+4.4%$32.00+67.2%+37.0%$848.48M$90.40M-5.77200Analyst ForecastRZLTRezolute2.6224 of 5 stars$9.29-0.5%$14.50+56.1%+84.6%$848.18MN/A-9.5840ABUSArbutus Biopharma1.3031 of 5 stars$4.46+1.1%$5.00+12.1%+14.1%$845.39M$6.17M-15.3890Positive NewsPHATPhathom Pharmaceuticals1.9702 of 5 stars$11.33-3.8%$17.50+54.5%-29.2%$835.72M$55.25M-2.40110News CoverageKODKodiak Sciences3.0138 of 5 stars$15.81+0.1%$13.00-17.8%+466.2%$834.58MN/A-4.1690Analyst ForecastVALNValneva2.5036 of 5 stars$10.95+12.8%$15.00+37.0%+96.0%$834.35M$183.52M-11.17700XNCRXencor3.5902 of 5 stars$11.55-0.2%$22.25+92.6%-40.7%$825.21M$110.49M-4.81280Analyst Forecast Related Companies and Tools Related Companies Relay Therapeutics Alternatives Taysha Gene Therapies Alternatives CorMedix Alternatives Urogen Pharma Alternatives Rezolute Alternatives Arbutus Biopharma Alternatives Phathom Pharmaceuticals Alternatives Kodiak Sciences Alternatives Valneva Alternatives Xencor Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredOctober 2025 Market Crash?Wall Street Legend Names #1 Stock [not NVDA] The greatest quantitative mind on Wall Street just revealed hi...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
